In the spring of 2026, researchers presented something the field of sports neuroscience has chased for two decades: a brain scan that might detect the signature of chronic traumatic encephalopathy in a living person. At the Society of Nuclear Medicine and Molecular Imaging annual meeting, a team described a new tau PET tracer, 18F-OXD-2314, and reported that in three retired collision-sport athletes with suspected CTE it lit up exactly where the disease deposits its abnormal protein — at the grey–white matter junction and deep in the white matter [source: Society of Nuclear Medicine and Molecular Imaging (SNMMI), 2026]. The investigators suggested it could reach patients "in the next two years."
It is a genuinely exciting result, and it is also three athletes. That tension — between a science that is advancing fast and a disease that still can only be confirmed after death — sits at the centre of everything written about concussion and CTE today. To read the headlines honestly, you have to separate three things that easily blur together: what can actually be diagnosed, what the exposure data correlate with, and what leagues and governing bodies have announced versus what has been proven to work.
The one fact that anchors everything: CTE is an autopsy diagnosis
Chronic traumatic encephalopathy is a neurodegenerative disease associated with repeated head impacts, and its defining feature is a specific pattern of tau protein around small blood vessels deep in the folds of the brain. That pattern can only be seen under a microscope, which means CTE can be confirmed only after death. As the Boston University CTE Center — the group that has done more than anyone to characterise the disease — states plainly, CTE "can only be confirmed after death" and cannot currently be definitively diagnosed in the living [source: Boston University CTE Center, 2024].
This is not a technicality; it shapes everything downstream. Because there is no accepted test in living people, researchers use a separate label — traumatic encephalopathy syndrome, or TES — to describe the clinical picture thought to reflect CTE. Consensus research criteria published in 2021 require a substantial history of repetitive head impacts, core problems with cognition or behavioural regulation, a progressive course, and no better explanation [source: Boston University CTE Center, 2024]. But TES is a research framework, not a diagnosis of CTE, and when guideline panels weighed whether to fold biomarkers into it, they judged the evidence premature.
How shaky is the bridge between the living syndrome and the post-mortem disease? It depends entirely on who you measure. One validity study of 193 brain donors, recruited across multiple banks with a spread of exposure levels, found TES criteria performed reasonably — roughly 79% sensitivity and 84% specificity against the actual neuropathology, and better still in older donors [source: Nature Medicine, 2026]. But a 2026 study in Nature Medicine applied the same criteria inside a single neurodegenerative-disease brain bank and got a very different answer: of 1,038 cases, 25 met TES criteria, and only 6 of those actually had CTE — a positive predictive value of about 24% [source: Nature Medicine, 2026]. The authors concluded that the criteria's apparent accuracy is driven largely by exposure history rather than the clinical features themselves, and warned against telling living athletes they likely have a disease that cannot be confirmed.
That is the measurement boundary, stated honestly. The 2026 tau PET tracer is aimed squarely at crossing it — but with three suspected cases and no autopsy confirmation in those living subjects, it belongs in the column marked emerging, not settled [source: Society of Nuclear Medicine and Molecular Imaging (SNMMI), 2026].
The exposure data have genuinely strengthened
If diagnosis in the living is the field's weak point, the link between how much head impact someone absorbs and how likely their brain is to show CTE is its strong one — and it has been getting stronger.
Consider the athletes who die young. In the largest series of its kind, Boston University examined the brains of 152 contact- and collision-sport athletes who died before the age of 30, donated between 2008 and 2022. Just over 41% — 63 of them — had neuropathological CTE, and most were amateurs: youth, high school, and college players rather than professionals [source: JAMA Neurology, 2023]. The series also included the first American woman athlete diagnosed with CTE, a college soccer player who died at 28. On average, those with CTE had played several years longer than those without.
A critical caveat has to travel with that 41% every time it is quoted. Brain-bank donors are not a random sample of athletes. Families often donate precisely because they noticed troubling symptoms, which means these cohorts are enriched for disease by design. Community brain banks that collect more representative samples report CTE in fewer than 1% of brains [source: JAMA Neurology, 2023]. The 41% is a real and sobering finding about a selected group; it is emphatically not the risk that any given young athlete faces.
What makes the recent evidence persuasive is not any single alarming number but the shape it takes across sports. In December 2024, researchers examined 77 deceased male ice hockey players and found that the odds of CTE rose about 34% for every year the athlete had played — a dose-response relationship — with CTE present in 18 of 19 former NHL players but only a small minority of those who never played beyond youth or high school levels [source: JAMA Network Open, 2024]. Years of play stood in for cumulative hits: the checking, the collisions, the boards.
And the "hits" that matter may not be the ones anyone notices. Analysing 631 former American-football players, a 2023 study found that 71% had some degree of CTE, and — more importantly — that the cumulative force of head impacts predicted the disease better than the number of impacts, the years played, or even the number of diagnosed concussions [source: Nature Communications, 2023]. In other words, it is the accumulated load of ordinary sub-concussive knocks, not just the dramatic concussions, that tracks most closely with the pathology.
Here the second distinction becomes essential. All of this is correlation and dose-response at the level of populations. It tells you that more cumulative force, across more years, in more players, associates with more CTE. It does not, and cannot, tell you which individual will develop the disease — because there is still no way to see it in a living brain, and because plenty of heavily exposed athletes never develop severe disease. The evidence has moved decisively toward "repeated head impact is a cause of CTE" as a general matter, while leaving "will this person get it?" genuinely unanswerable for now.
What the leagues have changed — and what that does and doesn't prove
The third layer is the one most vulnerable to spin, because a rule change is easy to announce and hard to evaluate. Governing bodies have, to their credit, moved. The question is what their moves have actually been shown to accomplish.
In soccer, England's Football Association has begun phasing deliberate heading out of youth football entirely. From the 2024–25 season the ban on deliberate headers applies to the youngest age groups, extending up through the under-11s over the following seasons, with an indirect free kick awarded against a deliberate header [source: The Football Association, 2024]. The policy follows a large trial and a body of research including the Glasgow FIELD study, which found former professional footballers were roughly three and a half times more likely to be diagnosed with dementia than matched members of the general population [source: NEJM / University of Glasgow (FIELD study), 2019]. That dementia association is well evidenced. But the heading ban itself is a precaution: it reduces young players' exposure to head impacts, which is a sound rationale, yet no outcome study has — or could yet — show that this specific rule lowers future rates of CTE or dementia. Reduced exposure is the measured effect; reduced disease is the hoped-for one.
American youth football shows the same gap between mechanism and proof more concretely. The Centers for Disease Control and Prevention reports that young athletes in tackle football sustain roughly 15 times as many head impacts as those in flag football, and that when one program cut contact practices from three or more days a week to two or fewer, head impacts across the season fell by 42% [source: CDC, 2024]. Those are measured reductions in exposure, and reducing exposure is exactly what the dose-response data suggest should help. But a 42% drop in head impacts is not the same as a demonstrated drop in CTE, and it is important to keep the claim the size of the evidence: the intervention plausibly reduces a known risk factor; it has not been shown to reduce the disease.
The courtrooms, described accurately
Nowhere is the pressure to overstate — or understate — the science greater than in litigation, and here precision matters most.
The National Football League settled a class action over concussion-related injuries in 2015. The settlement pays qualifying diagnoses on a sliding scale — on the order of several million dollars for post-mortem CTE within a defined cutoff, for Alzheimer's, and for dementia — and the league says it has paid more than $1.2 billion to over 1,600 former players and their families [source: Washington Post, 2024]. But the settlement has a revealing limit that follows directly from the science: because CTE cannot be diagnosed in the living, living players cannot claim for it. And a 2024 Washington Post investigation documented how denials, delays, and medical loopholes have kept many families from the payouts the settlement seemed to promise [source: Washington Post, 2024]. The case is settled; how it is administered remains contested.
Rugby's reckoning is still unfolding. More than 1,100 former rugby union and rugby league players — including the 2003 World Cup winner Steve Thompson and the former Wales captain Ryan Jones — are pursuing group litigation in the UK against World Rugby and the sport's national governing bodies, arguing they failed in a duty of care to protect players from concussive and sub-concussive impacts now linked to early dementia and other neurological disease [source: Sports Litigation Alert, 2024]. World Rugby has filed a defence denying liability, contending that injury is a "foreseeable and inherent risk" of the sport and disputing that the science reliably linked non-concussive head-acceleration events to lasting harm at the relevant time [source: Sports Litigation Alert, 2024]. No settlement has been reached, and it would be wrong to report the outcome as decided in either direction; the case is a live dispute about exactly the scientific uncertainty this article has described.
How to hold all of this at once
The honest 2026 picture is neither the alarmist version, in which every header dooms a child, nor the dismissive one, in which CTE is a media panic. Both misread the evidence by collapsing its layers.
Diagnosis in the living remains the hard boundary: CTE is confirmed at autopsy, TES is a research label whose accuracy swings with the sample, and the promising tau PET work is early. The exposure evidence, by contrast, is real and strengthening across football, ice hockey, and soccer, pointing consistently to cumulative force — including the quiet sub-concussive hits — as what matters, even as it stays silent on any one person's fate. And the institutional response is a set of reasonable precautions that reduce measured exposure but have not yet been proven to reduce the disease.
Three developments will tell you whether the picture sharpens. Whether a validated biomarker finally lets doctors diagnose CTE in the living without over-calling it. Whether long-term studies show that the rule changes now reshaping youth sport actually lower disease rates, rather than just impact counts. And whether the courts, weighing the same evidence, decide what a governing body owed the people who played. Until then, the useful posture is the one the science supports: take the exposure data seriously, hold the individual predictions lightly, and keep the announcements separate from the outcomes.